信使核糖核酸疫苗：基于微小核糖核酸的可控生物分布与定向佐剂作用
mRNA vaccines: miRNA-based controlled biodistribution and directed adjuvantation.
作者信息
Brook Byron, Goetz Morgan, Duval Valerie, Micol Romain, Dowling David J
机构信息
Precision Vaccines Program, Boston Children's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Combined Therapeutics Incorporated, Boston, MA 02135, USA.
出版信息
Trends Immunol. 2025 May;46(5):357-360. doi: 10.1016/j.it.2025.03.004. Epub 2025 Apr 22.
The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.
可电离的信使核糖核酸-脂质纳米颗粒（mRNA-LNP）核酸载体的发展推动了2019冠状病毒病（COVID-19）mRNA疫苗BNT162b2和mRNA-1273的临床转化。在此，我们讨论对mRNA疫苗进行合理改进的见解，重点关注用于控制mRNA-LNP生物分布的LNP修饰、基于微小RNA的编码转录本生物分布控制以及精准佐剂策略。
Zotero 插件